{"product_id":"essential-manual-of-24-hour-blood-pressure-management-isbn-9781119799368","title":"Essential Manual of 24-Hour Blood Pressure Management","description":"\u003cb\u003eESSENTIAL MANUAL OF 24-HOUR BLOOD PRESSURE MANAGEMENT\u003c\/b\u003e \u003cp\u003eHypertension is one of the greatest threats to human health. The World Health Organization (WHO) estimates that 1.13 billion people worldwide have hypertension. In 2017, new guidelines for managing hypertension were published by the American Hypertension Association (AHA), guidelines which lowered the diagnosis thresholds of hypertension, and thereby increased the prevalence of hypertension. As such, hypertension is now recognized as a more serious and widespread a condition than ever before. \u003c\/p\u003e\u003cp\u003eIn this new edition of the \u003ci\u003eEssential Manual of 24-Hour Blood Pressure Management\u003c\/i\u003e, the author emphasizes that lowering the blood pressure (BP) and restoring the BP profile with adequate circadian rhythm is essential for a long life without cardiovascular events. The author also introduces updated evidence for managing hypertension throughout 24-hour periods, from morning to nocturnal hypertension. \u003c\/p\u003e\u003cp\u003eThe \u003ci\u003eEssential Manual of 24-Hour Blood Pressure Management\u003c\/i\u003e, Second Edition, will be an essential companion for doctors who wish to provide evidence-based medicine and be familiar with the most cutting edge technology on monitoring BP. Medical researchers and students will also value the author’s many insights, drawn from his distinguished career. \u003c\/p\u003e\u003cp\u003eAuthor biography, xi\u003c\/p\u003e \u003cp\u003ePreface – Direction to “Perfect 24-hour Blood Pressure Control”, xv\u003c\/p\u003e \u003cp\u003eAcknowledgments, xix\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Evidence and scientific rationale for ambulatory blood pressure monitoring (ABPM), 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eDiurnal BP variation and the concept of “perfect 24-hour BP control”, 1\u003c\/p\u003e \u003cp\u003eNocturnal hypertension and nocturnal BP dipping status, 3\u003c\/p\u003e \u003cp\u003eNocturnal BP dipping status, 3\u003c\/p\u003e \u003cp\u003eNon-dipper patterns of BP and pulse rate, 3\u003c\/p\u003e \u003cp\u003eRiser pattern of BP and cardiovascular disease risk, 4\u003c\/p\u003e \u003cp\u003eRiser pattern and HF, 7\u003c\/p\u003e \u003cp\u003eRiser pattern and brain damage, 15\u003c\/p\u003e \u003cp\u003eNocturnal hypertension, 17\u003c\/p\u003e \u003cp\u003eAssociated Conditions and Mechanisms of Nocturnal Hypertension, 20\u003c\/p\u003e \u003cp\u003eMechanism of cardiovascular risk of nocturnal hypertension, 22\u003c\/p\u003e \u003cp\u003eExtreme dipping, 24\u003c\/p\u003e \u003cp\u003eMorning surge in BP, 27\u003c\/p\u003e \u003cp\u003eDefinition of MBPS, 33\u003c\/p\u003e \u003cp\u003eMorning BP surge and cardiovascular disease, 34\u003c\/p\u003e \u003cp\u003eMorning BP surge and organ damage, 37\u003c\/p\u003e \u003cp\u003eDeterminants of MBPS, 43\u003c\/p\u003e \u003cp\u003eMechanism of morning risk, 44\u003c\/p\u003e \u003cp\u003eMorning BP surge and hemostatic abnormalities, 46\u003c\/p\u003e \u003cp\u003eVascular mechanism of exaggerated morning BP surge, 49\u003c\/p\u003e \u003cp\u003eBP Variability and systemic hemodynamic atherothrombotic syndrome (SHATS), 52\u003c\/p\u003e \u003cp\u003eThe resonance hypothesis of BP surge, 53\u003c\/p\u003e \u003cp\u003eOrthostatic hypertension, 54\u003c\/p\u003e \u003cp\u003eAmbulatory BP variability, 57\u003c\/p\u003e \u003cp\u003eVisit-to-visit variability in office BP, 58\u003c\/p\u003e \u003cp\u003eVicious cycle between BP variability and vascular disease—SHATS, 59\u003c\/p\u003e \u003cp\u003eWhite-coat and masked hypertension, 71\u003c\/p\u003e \u003cp\u003eWhite-coat hypertension, 73\u003c\/p\u003e \u003cp\u003eMasked hypertension, 75\u003c\/p\u003e \u003cp\u003eAdvances in ABPM, 75\u003c\/p\u003e \u003cp\u003eDevelopment of information and communication technology-based multi-sensor (IMS)-ABPM, 75\u003c\/p\u003e \u003cp\u003eNew ABPM indices, 77\u003c\/p\u003e \u003cp\u003eHI-JAMP registry, 82\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Scientific rationale for HBPM, 85\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eFive prospective, general practitioner-based, home BP studies, 85\u003c\/p\u003e \u003cp\u003eMorning hypertension, 85\u003c\/p\u003e \u003cp\u003eControl status of morning home BP in the J-HOP study, 88\u003c\/p\u003e \u003cp\u003eEvidence for morning hypertension control, 89\u003c\/p\u003e \u003cp\u003eHome BP variability, 99\u003c\/p\u003e \u003cp\u003eMorning–evening difference (ME-dif), 99\u003c\/p\u003e \u003cp\u003eSD, CV, ARV, and VIM of home BP, 101\u003c\/p\u003e \u003cp\u003eMaximum home SBP, 103\u003c\/p\u003e \u003cp\u003eOrthostatic Home BP Change, 103\u003c\/p\u003e \u003cp\u003eSeasonal variation of home BP and “thermosensitive hypertension”, 109\u003c\/p\u003e \u003cp\u003eAlcohol, 113\u003c\/p\u003e \u003cp\u003eDaytime hypertension (stress hypertension), 115\u003c\/p\u003e \u003cp\u003eNighttime HBPM, 115\u003c\/p\u003e \u003cp\u003eCutting-edge of HBPM, 115\u003c\/p\u003e \u003cp\u003eBasic nighttime home BP monitoring (Medinote), 119\u003c\/p\u003e \u003cp\u003eClinical evidence using nocturnal HBPM: J-HOP nocturnal BP study, 119\u003c\/p\u003e \u003cp\u003eTrigger nighttime BP monitoring, 127\u003c\/p\u003e \u003cp\u003eIT-based trigger nighttime BP monitoring system and the SPREAD study, 133\u003c\/p\u003e \u003cp\u003eCPAP adherence and nighttime BP surge, 135\u003c\/p\u003e \u003cp\u003eAntihypertensive medication on nighttime BP surge, 139\u003c\/p\u003e \u003cp\u003eWrist home HBPM and WISDOM Night study, 145\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Practical use of ABPM and HBPM, 147\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eConcept and positioning of ABPM and HBPM in guidelines, 147\u003c\/p\u003e \u003cp\u003eRecent guidelines, 147\u003c\/p\u003e \u003cp\u003eDiagnosis of masked and white-coat hypertension, 147\u003c\/p\u003e \u003cp\u003eDefinition of morning hypertension, 148\u003c\/p\u003e \u003cp\u003eDefinition of nocturnal hypertension, 150\u003c\/p\u003e \u003cp\u003eWhen to use HBPM and ABPM, 150\u003c\/p\u003e \u003cp\u003eClinically suspected SHATS, 152\u003c\/p\u003e \u003cp\u003eCardio-ankle vascular index (CAVI), 154\u003c\/p\u003e \u003cp\u003eCoupling study, 154\u003c\/p\u003e \u003cp\u003eHow to measure home BP, 155\u003c\/p\u003e \u003cp\u003eNighttime home BP measurement schedule, 159\u003c\/p\u003e \u003cp\u003eABPM parameters, 162\u003c\/p\u003e \u003cp\u003e24-hour BP, 166\u003c\/p\u003e \u003cp\u003eDaytime BP and nighttime BP, 166\u003c\/p\u003e \u003cp\u003eMorning BP parameters, 166\u003c\/p\u003e \u003cp\u003eNighttime BP parameters, 166\u003c\/p\u003e \u003cp\u003eMBPS parameters, 166\u003c\/p\u003e \u003cp\u003eNighttime BP surge parameters, 166\u003c\/p\u003e \u003cp\u003eNighttime BP dipping parameters, 167\u003c\/p\u003e \u003cp\u003eABPM-defined hypertension subtypes, 167\u003c\/p\u003e \u003cp\u003eHome and ambulatory BP-guided management of hypertension, 167\u003c\/p\u003e \u003cp\u003eSTEpwise-Personalized 24-hour BP control approach (STEP24 approach), 167\u003c\/p\u003e \u003cp\u003eTargeting morning hypertension (Step 1), 167\u003c\/p\u003e \u003cp\u003eTargeting nocturnal hypertension (Step 2), 171\u003c\/p\u003e \u003cp\u003ePressor mechanism-based nighttime BP management strategy, 173\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 BP targets, when to initiate antihypertensive therapy, and nonpharmacological treatment, 177\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eClinical implications of antihypertensive treatment, 177\u003c\/p\u003e \u003cp\u003eSPRINT and automated office BP, 177\u003c\/p\u003e \u003cp\u003eMeta-analysis of antihypertensive trials, 177\u003c\/p\u003e \u003cp\u003eWhen to initiate antihypertensive therapy, 178\u003c\/p\u003e \u003cp\u003ePatient preference, 178\u003c\/p\u003e \u003cp\u003eSodium intake, 179\u003c\/p\u003e \u003cp\u003eOther dietary requirements, 181\u003c\/p\u003e \u003cp\u003eExercise, 183\u003c\/p\u003e \u003cp\u003eSleep hygiene, 185\u003c\/p\u003e \u003cp\u003eHousing condition, 185\u003c\/p\u003e \u003cp\u003eApplications and algorithms to facilitate lifestyle modification: CureAPP, 187\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Antihypertensive medication, 189\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eConcept of 24-hour BP lowering including nighttime and morning BPs, 189\u003c\/p\u003e \u003cp\u003eChronotherapy, 189\u003c\/p\u003e \u003cp\u003eAntihypertensive drug choice, 190\u003c\/p\u003e \u003cp\u003eCalcium channel blockers, 190\u003c\/p\u003e \u003cp\u003eAmlodipine, 194\u003c\/p\u003e \u003cp\u003eNifedipine, 195\u003c\/p\u003e \u003cp\u003eCilnidipine, 197\u003c\/p\u003e \u003cp\u003eAzelnidipine, 199\u003c\/p\u003e \u003cp\u003eAngiotensin-converting enzyme inhibitors, 201\u003c\/p\u003e \u003cp\u003eAngiotensin receptor blockers (ARBs), 201\u003c\/p\u003e \u003cp\u003eValsartan, 201\u003c\/p\u003e \u003cp\u003eTelmisartan, 204\u003c\/p\u003e \u003cp\u003eCandesartan, 204\u003c\/p\u003e \u003cp\u003eOlmesartan, 205\u003c\/p\u003e \u003cp\u003eAzilsartan, 206\u003c\/p\u003e \u003cp\u003eDiuretics, 212\u003c\/p\u003e \u003cp\u003eAlpha-adrenergic blockers and beta-adrenergic blockers, 214\u003c\/p\u003e \u003cp\u003eMineralocorticoid receptor blockers (MRB), 215\u003c\/p\u003e \u003cp\u003eAngiotensin receptor-neprilysin inhibitor (ARNi), 217\u003c\/p\u003e \u003cp\u003eEndothelin receptor antagonists (ERA), 221\u003c\/p\u003e \u003cp\u003eCombination therapy, including single pill combinations, 222\u003c\/p\u003e \u003cp\u003eFirst-line therapy, 222\u003c\/p\u003e \u003cp\u003eSecond-line therapy, 222\u003c\/p\u003e \u003cp\u003eClinical trials of antihypertensive combination therapy, 226\u003c\/p\u003e \u003cp\u003eManagement of resistant hypertension, 238\u003c\/p\u003e \u003cp\u003eThird-line therapy, 238\u003c\/p\u003e \u003cp\u003eFourth-line therapy, 239\u003c\/p\u003e \u003cp\u003eSGLT2 inhibitors, 240\u003c\/p\u003e \u003cp\u003eSACRA study, 243\u003c\/p\u003e \u003cp\u003eSHIFT-J study, 244\u003c\/p\u003e \u003cp\u003eLUSCAR study, 248\u003c\/p\u003e \u003cp\u003eSummary, 250\u003c\/p\u003e \u003cp\u003eOther BP-lowering therapies, 252\u003c\/p\u003e \u003cp\u003eHypnotics, 252\u003c\/p\u003e \u003cp\u003eXOR inhibitor, 252\u003c\/p\u003e \u003cp\u003eHerbal medication, 253\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Renal denervation, 255\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eUnsolved issues in the treatment of hypertension and the era for renal denervation, 255\u003c\/p\u003e \u003cp\u003eHypothesis of perfect 24-hour BP control by renal denervation, 256\u003c\/p\u003e \u003cp\u003eHistory, 257\u003c\/p\u003e \u003cp\u003eAdvances in devices, 262\u003c\/p\u003e \u003cp\u003eSymplicity spyral system (radiofrequency thermal ablation), 262\u003c\/p\u003e \u003cp\u003eIberis® system, 264\u003c\/p\u003e \u003cp\u003eParadise system (ultrasonic thermal ablation), 264\u003c\/p\u003e \u003cp\u003ePeregrine system (trans-arterial alcohol injection), 265\u003c\/p\u003e \u003cp\u003eOther energy modalities, 266\u003c\/p\u003e \u003cp\u003eEvidence for renal denervation treatment of hypertension from Sham-controlled trials, 266\u003c\/p\u003e \u003cp\u003eSPYRAL trials, 266\u003c\/p\u003e \u003cp\u003eRadiance-Htn Solo study, 268\u003c\/p\u003e \u003cp\u003eEvidence from Japanese populations, 269\u003c\/p\u003e \u003cp\u003eThe Global Symplicity Registry (GSR), 269\u003c\/p\u003e \u003cp\u003eSafety of the renal denervation procedure, 270\u003c\/p\u003e \u003cp\u003e24-hour BP lowering profile for cardiovascular protection, 270\u003c\/p\u003e \u003cp\u003eResponders and clinical indications, 272\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Blood pressure linked telemedicine and telecare, 278\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eAnticipation medicine, 278\u003c\/p\u003e \u003cp\u003eInnovation technology, 280\u003c\/p\u003e \u003cp\u003eConcept of “trigger” management, 282\u003c\/p\u003e \u003cp\u003eMultisensors and the real-time hybrid Wi-SUN\/Wi-Fi transmission system, 283\u003c\/p\u003e \u003cp\u003eAI and anticipation models, 284\u003c\/p\u003e \u003cp\u003eDevelopment of wearable beat-by-beat (surge) BP monitoring, 285\u003c\/p\u003e \u003cp\u003eSurge index, 292\u003c\/p\u003e \u003cp\u003eDisaster cardiovascular prevention (DCAP) network, 294\u003c\/p\u003e \u003cp\u003eSuccessful anticipation model of ICT-based BP control, 302\u003c\/p\u003e \u003cp\u003eDisaster hypertension, 302\u003c\/p\u003e \u003cp\u003eCOVID-19 era, 305\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Asia perspectives, 311\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eWhat is the HOPE Asia Network?, 311\u003c\/p\u003e \u003cp\u003eHOPE Asia Network achievements, 312\u003c\/p\u003e \u003cp\u003eCharacteristics of cardiovascular disease in Asia, 315\u003c\/p\u003e \u003cp\u003eObesity and salt intake in Asia, 315\u003c\/p\u003e \u003cp\u003e24-hour ambulatory BP profile in Asia, 320\u003c\/p\u003e \u003cp\u003eAsia BP@Home Study, 325\u003c\/p\u003e \u003cp\u003eReferences, 328\u003c\/p\u003e \u003cp\u003eIndex, 368\u003c\/p\u003e \u003cp\u003e \u003c\/p\u003e \u003cp\u003e\u003cb\u003eAbout the Author\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eDr Kazuomi Kario, MD, PhD, FACC, FAHA, FESC\u003c\/b\u003e graduated from Jichi Medical School in 1986. He is currently Professor and Chairman of Cardiovascular Medicine, Jichi Medical University School of Medicine, Tochigi, Japan.  \u003c\/p\u003e\u003cp\u003eHypertension is one of the greatest threats to human health. The World Health Organization (WHO) estimates that 1.13 billion people worldwide have hypertension. In 2017, new guidelines for managing hypertension were published by the American Hypertension Association (AHA), guidelines which lowered the diagnosis thresholds of hypertension, and thereby increased the prevalence of hypertension. As such, hypertension is now recognized as a more serious and widespread a condition than ever before.\u003c\/p\u003e \u003cp\u003eIn this new edition of the \u003ci\u003eEssential Manual of 24-Hour Blood Pressure Management\u003c\/i\u003e, the author emphasizes that lowering the blood pressure (BP) and restoring the BP profile with adequate circadian rhythm is essential for a long life without cardiovascular events. The author also introduces updated evidence for managing hypertension throughout 24-hour periods, from morning to nocturnal hypertension. \u003c\/p\u003e\u003cp\u003eThe \u003ci\u003eEssential Manual of 24-Hour Blood Pressure Management\u003c\/i\u003e, Second Edition, will be an essential companion for doctors who wish to provide evidence-based medicine and be familiar with the most cutting edge technology on monitoring BP. Medical researchers and students will also value the author’s many insights, drawn from his distinguished career.\u003c\/p\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47989156348133,"sku":"NP9781119799368","price":71.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781119799368.jpg?v=1761783024","url":"https:\/\/k12savings.com\/es\/products\/essential-manual-of-24-hour-blood-pressure-management-isbn-9781119799368","provider":"K12savings","version":"1.0","type":"link"}